Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

53 > 4. Pharmaco > Flashcards

4. Pharmaco Flashcards

1
Q

Seizure

A

a paroxysmal (unexpected) event due to abnormal, hypersynchronous discharge from a mass of CNS neurons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

manifestation of seizure

A

Diverse manifestation: convulsion (observable) to an experience (subjective)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

is a single seizure due to correctable or avoidable circumstance (ie provoked) considered an epilepsy?

A

not an epilepsy (eg due to alcohol, hypoglycaemia, pyrexia, sleep deprivation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

epilepsy pathophysiology

A

a seizure occurs when there is excessive synchronous depolarisation due to unbalanced excitatory and inhibitory receptor/ ion channel function which favours depolarisation → dysregulated/ unregulated discharge

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

types of seziure

A
  • generalised (both hemisphere affected, consciousness affected) -> tonic clonic, absence
  • partial seizures (half hemisphere affected) -> simple (consciousness not impaired), complex (consciousness impaired)
  • status epilepticus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

rationale for anti-epileptics

A
  • decrease membrane excitability by altering Na+ and Ca2+ conductance during action potential
  • enhanced effects of inhibitory GABA NT (GABA when bind to receptor opens Cl- channels allowing Cl- ions to enter)
  • drugs should be individualised and started on monotherapy initially
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

phenytoin MOA

A

block voltage-dependent Na+ channels → decreases Na+ entry → decrease AP discharge → decrease excitation of neuron

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

phenytoin indication

A

for all types of seizures except absence seizures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

characteristics of phenytoin

A
  • relative narrow therapeutic range
  • teratogenic
  • non-linear saturation kinetics profile (need TDM)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

MOA of carbamazepine

A

blockade of voltage-dependent Na+ channels (similar to phenytoin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Indiction of carbamazepine

A

for all types of seizures except absence seizures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

characteristics of carbamazepine

A

Autoinduction: hepatic CYP450 enzyme inducer, T1/2 shortens with repeated/increasing doses → accelerate metabolism of carbamazepine and other drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

carbamazepine pgx

A

HLA-B*1502 positive - increased risk of SJS/ TEN (require PGx testing before drug initiation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MOA of valproate

A
  • blockade of voltage-dependent Na+ and Ca2+ channels
  • inhibit GABA transaminase (enzyme that breakdown GABA) → increase GABA (inhibitory NT)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

indication for valproate

A

for all types of seizures including absence seizures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

characteristics of valproate

A

strongly bound to plasma proteins, displaces other antiepileptics/ drugs (ie DDI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Adverse effects of antiepileptics (dose related)

A

drowsiness, confusion, nystagmus (shifty eyes), ataxia (unable to keep balance), slurred speech, nausea, unusual behaviour, mental changes, coma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Adverse effects of antiepileptics (non dose related)

A

hirsutism, acne, gingival hyperplasia (swollen gums), folate deficiency, osteomalacia (softening of bone), hypersensitivity (eg SJS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

MOA of benzodiazepines

A

bind to regulatory site of of GABA receptors (different binding site from GABA) → increase GABA mediated Cl- ions influx → hyperpolarisation → neurons not firing

  • potentiates inhibitory effect of GABA (only works when GABA is present)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

acute toxicity/overdose of benzodiazepines

A

acute toxicity/ overdose - cause severe respiratory depression, especially when used concurrently with alcohol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

tx of benzodiazepine overdose

A

flumazenil (benzodiazepine competitive antagonist)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

SE of benzodiazepine

A

drowsiness, confusion, amnesia (memory loss), impaired muscle coordination, tolerance and dependence

23
Q

MOA of phenobarbital

A

potentiates GABA mediated Cl- ions entry (inhibitory effects) but different site from benzodiazepines (flumazenil not effective for overdose of barbiturate)

24
Q

SE of phenobarbital

A

Severe withdrawal symptoms (more severe than benzodiazepines), greater risk of causing CNS effects especially at higher doses as compared to benzodiazepines

25
Levetiracetam indication
- adjunctive tx - can be used as monotherapy for partial onset seizures - not effective for absence seizures
26
PK characteristics of levetiracetam
- highly soluble and permeable - PK profile is linear with low and intra and inter subject variability (different from phenytoin)
27
route of administration for levetiracetam
IV infusionor PO
28
SE of levetiracetam
- common: headache, vertigo, cough, depression, insomnia - rare: agranulocytosis, suicide, delirium, dyskinesia (involuntary movement)
29
MOA of lamotrigine
- blocks voltage-gated sodium channels - inhibit release of glutamate
30
indication of lamotrigine
- adjunctive/ monotherapy tx - can be used as monotherapy for absence seizures (alternative to valproate)
31
PK of lamotrigine
- linear PK, oral route (chewable) - shorter half-life in children - half-life reduced with co-administration with carbamazepine and phenytoin and increased with valproate
32
SE of lamotrigine
- common: headache, irritability/ aggression, tiredness - rare: agranulocytosis, hallucination, movement disorders, SJS/TEN, hepatic failure
33
indication of topiramate
- monotherapy for partial seizures and generalised seizures (tonic clonic) - Prophylaxis of migraine headaches in adults (not for acute tx)
34
PK characteristics of topiramate
- linear PK, oral route, long plasma half life - renal clearance - not a potent inducer of drug-metabolising enzymes
35
SE of topiramate
- common: depression, somnolence, fatigue, nausea, weight change - rare: neutropenia, mania, tremor, transient blindness, SJS/TEN, hepatic failure
36
when are TDM needed?
1. Assess compliance 2. Assess symptoms due to ASM toxicity 3. Titration of phenytoin dose (phenytoin needs TDM)
37
headache/migraine pathophysiology
vasodilation of intracranial extracerebral blood vessels → activation of perivascular trigeminal nerves → release vasoactive neuropeptides → neurogenic inflammation
38
sx of headache/migraine
nausea, vomiting, photophobia, phonophobia (scared of loud noises)
39
role of serotonin in migraine
serotonin is an important mediator of migraine - Serotonin agonist for vascular and neuronal 5HT1 receptor cause vasoconstriction of meningeal blood vessels and inhibit vasoactive neuropeptide release and pain signal transmission.
40
MOA of cafergot
tonic action on vascular smooth muscles in the intracranial extracerebral blood vessels → vasoconstriction by stimulating alpha-adrenergic and 5HT (1B & 1D) receptors
41
indication of cafergot
for ACUTE tx of migraine
42
PK of cafergot
- oral/rectal, rapidly absorbed (max plasma conc in 1.5-2hr) - high plasma protein binding, low F - inhibit CYP3A4 (avoid use with other 3A inhibitors like macrolides → can elevate ergot toxicity causing vasospasm and tissue ischemia)
43
SE of cafergot
- common: nausea and vomiting - rare: hypersensitivity, MI, ergotism (vascular ischemia)
44
DDI
Should not be used with other vasoconstrictor agents (eg ergot derivatives, sumatriptan, 5HT1 agonists)
45
MOA of sumatriptan
- selective 5HT 1B/1D receptor agonist → selectively constricts carotid arterial circulation (does not affect cerebral blood flow) - inhibit trigeminal nerve activity (eg vasoactive peptides and inflammatory mediators)
46
Indication of sumatriptan
acute tx of migraine with or without aura
47
PK of sumatriptan
- oral, nasal, IV - rapidly absorbed, low plasma binding, eliminated primarily by MAO (type A)
48
CI of sumatriptan
hypersensitivity to triptans, concomitant use with MAOi, MI
49
SE of sumatriptan
- common: dysgeusia (unpleasant taste), transient BP rise, flushing, cold, pressure, tightness, serotonin syndrome - rare: minor disturbances in liver function tests
50
MOA of erenumab
is a monoclonal antibody that inhibits CGRP receptors - CGRP are nociceptive neuropeptide at the trigeminal ganglion, a vasodilator - CGRP increase with migraine
51
indication of erenumab
prophylaxis of migraine in adults who have at least 4 migraine days per mth
52
PK characteristics of erenumab
- SC q monthly, benefit seen within 3mths - linear kinetics at therapeutic doses (CGRP receptor binding is saturated)
53
SE of erenumab
hypersensitivity reactions, injection site reactions, constipation, prutitis

53 (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions